Zoetis Stock Tumbles on Safety Concerns for Arthritis Shots for Pets
Zoetis Inc. experienced a sharp decline in its stock price following a report by The Wall Street Journal indicating potential harm to pets from its arthritis shots, Librela and Solensia, raising concerns among investors and prompting an investigation into possible violations of federal securities laws.
Zoetis Inc, a leading animal health company, saw its stock price plummet by around 8.4% to $149.12 midday Friday, following a report by The Wall Street Journal. The report raised concerns over the safety of the company's arthritis shots, Librela and Solensia, which are used to treat osteoarthritis in dogs and cats. According to the report, these medications, which target the nerve growth factor protein, could potentially worsen pre-existing nerve conditions or cause other medical issues in pets. Health regulators both in the United States and Europe have received numerous complaints regarding side effects from these drugs. Despite these reports, Zoetis responded by indicating that these adverse events only represent a small fraction of the over 18 million doses administered globally.
In response to the emerging concerns, the law firm Levi & Korsinsky has initiated an investigation into possible violations of federal securities laws by Zoetis Inc. following the significant drop in the company's stock value by more than 4% after the news was published on April 12, 2024. Levi & Korsinsky, a nationally-recognized securities litigation firm with a track record of securing substantial recoveries for shareholders and winning high-stakes cases, is urging investors who have suffered losses to contact them to discuss their legal rights. The firm has been ranked in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its prominence and success in securities litigation in the United States.
Zoetis's situation underscores the intricate balance companies must maintain between innovation in veterinary medicine and the imperative to ensure safety and efficacy. The investigation by Levi & Korsinsky not only seeks to address potential losses faced by Zoetis investors but also highlights the broader implications for regulatory oversight and consumer trust in veterinary pharmaceuticals. Investors and pet owners alike are keenly watching how Zoetis will navigate these legal and regulatory challenges, and what steps will be taken to ensure the safety of its products moving forward.
Articles published about this story
- proactiveinvestors.com
More stories
Robinhood Markets, Inc. has seen its stock price surge to a new 52-week high, driven by positive upgrades and a favorable market environment. The company's performance in 2024 and its position in the penny stock market have also contributed to its recent success.
Hino Motors, a subsidiary of Toyota, faces criminal charges in the U.S. for selling over 105,000 non-compliant diesel engines, marking a significant scandal in the automotive industry.
Instagram, owned by Meta, experienced a significant outage in the US on January 15, 2025, which was largely resolved by the afternoon, as reported by Downdetector.
BlackRock Inc. reported a record $11.6 trillion in assets under management in Q4 2024, driven by strong market performance and strategic acquisitions, leading to a rise in its stock price.
- investiment.io
General Motors has signed a multi-billion dollar agreement with Vianode to secure synthetic graphite for its electric vehicle batteries, aiming to reduce reliance on China and enhance EV production.
- investiment.io
The Bank of New York Mellon Corporation (BNY) reported a robust Q4 2024, with earnings and revenue surpassing expectations, leading to a significant rise in its stock price.
JPMorgan Chase reported a record annual profit and a significant Q4 earnings beat, driven by a surge in investment banking fees and trading revenue, surpassing Wall Street expectations.
- investiment.io
Meta Platforms Inc. plans to cut approximately 5% of its workforce, focusing on low performers, as part of its ongoing efficiency drive. CEO Mark Zuckerberg announced the move in an internal memo, signaling an 'intense year' ahead with a focus on AI, smart glasses, and social media innovation.
Pfizer is set to significantly reduce its stake in Haleon, the maker of Sensodyne, to 7.3% through a £2.5 billion share sale, as announced by bookrunner J.P. Morgan.
Boeing's stock experienced a decline following a significant drop in aircraft deliveries in 2024, marking the lowest delivery numbers since the onset of the COVID-19 pandemic. The company faced challenges including a labor strike, production issues, and increased competition from Airbus.